RAFAEL HOLDINGS INC. CLASS B COMMON STOCK

Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

01 7 2021 07:00:01 提供 Nasdaq GlobeNewswire

Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress

30 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

29 6 2021 10:00:00 提供 Nasdaq GlobeNewswire

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

26 5 2021 08:00:00 提供 Nasdaq GlobeNewswire

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

30 3 2021 08:00:01 提供 Nasdaq GlobeNewswire

LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®

10 2 2021 08:00:00 提供 Nasdaq GlobeNewswire

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

19 1 2021 10:30:00 提供 Nasdaq GlobeNewswire

Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

13 1 2021 08:00:01 提供 Nasdaq GlobeNewswire